cyclophosphamide

Type: Keyphrase
Name: cyclophosphamide
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Researchers from Medical University Describe Findings in Stem Cells (Clofarabine/cyclophosphamide for debulking before stem cell transplantation)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news reporting from Vienna, Austria, by NewsRx journalists, research stated, "Allogeneic haematopoietic stem cell transplantation ... [Published Street Sweeper - 2 hours ago]
First reported Aug 19 2014 - Updated 8 hours ago - 1 reports

Carilzomib Alone Not Effective for Refractory Multiple Myeloma

the Cancer Therapy Advisor take:Amgen has announced disappointing results from their phase 3 study, Carfilzomib for Advanced Refractory Multiple Myeloma European Study (FOCUS) as carfilzomib (Kyprolis) did not reach its primary endpoint for the treatment ... [Published Chemotherapy Advisor - Aug 19 2014]
First reported Aug 17 2014 - Updated Aug 17 2014 - 1 reports

Stem Cell Transplantation

Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ... [Published Multiple Sclerosis Research - Aug 17 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Amgen's phase 3 FOCUS trial of Kyprolis in patients with multiple myeloma fails to meet primary endpoint

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, ... [Published PharmaBiz - Aug 16 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Kyprolis fails to meet primary endpoint in multiple myeloma

Results from a phase 3 trial have found that carfilzomib did not meet its primary endpoint of OS for the treatment of relapsed and advanced refractory multiple myeloma, the manufacturer announced today.In a phase 3 open-label study – FOCUS – the safety ... [Published Orthopedics Today - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 1 reports

Amgen Multiple Myeloma Drug Misses Phase 3 Endpoint

Amgen and its subsidiary Onyx Pharmaceuticals Inc. announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS). The 315-patient, ... [Published Drug Discovery and Development - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Amgen cancer drug fails key test

Amgen’s new rare cancer drug has failed in a late-stage trial just a year after the US biotech spent $10.4 billion to acquire its manufacturer.Kyprolis (carfilzomib), a proteasome inhibitor, is already approved in the US for the treatment of patients ... [Published Pharmafocus - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

HSV-Related Oral Mucositis in Patients With Lymphoma

Maria D. Guerrero, RN, ANP-C, AOCNP, Karen K. Swenson, RN, PhD, AOCNDisclosuresOncol Nurs Forum. 2014;41(3):327-330.Abstract and IntroductionA 58-year-old man named J.S. was diagnosed with non-Hodgkin lymphoma and underwent treatment with standard rituximab, ... [Published General Medicine eJournal - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Findings from Ghent University Update Understanding of Gene Therapy (Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA...

at 14:13 PM EDT Findings from Ghent University Update Understanding of Gene Therapy (Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication) By ... [Published Industrial Info Financials - Aug 13 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 2 reports

Research Conducted at Fred Hutchinson Cancer Research Center Has Updated Our Knowledge about Hematopoietic (Cyclophosphamide followed by intravenous...

Research Conducted at Fred Hutchinson Cancer Research Center Has Updated Our Knowledge about Hematopoietic (Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and ...) By a News ... [Published Wall Street Business Network - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours

by Monika Michałowska, Stanislaw Winiarczyk, Łukasz Adaszek, Wojciech Łopuszyński, Zbigniew Grądzki, Brian Salmons, Walter H. GünzburgBased upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome ... [Published Plosone.org - Aug 06 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

High Response Rate and Good Safety Profile for Carfilzomib Plus Cyclophosphamide and Dexamethasone

By Charlotte BathJuly 25, 2014, Volume 5, Issue 12A multicenter, open-label phase II trial found that the selective proteasome inhibitor carfilzomib (Kyprolis), in combination with cyclophosphamide and dexamethasone produced high complete response rates ... [Published The ASCO Post - Jul 24 2014]

Quotes

...According to news reporting from Vienna, Austria, by NewsRx journalists, research stated, "Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative rescue therapy for patients (pts) with chemotherapy-refractory acute leukaemia...."
...Pablo J Cagnoni, M D , President, Onyx, said, "While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results from the recent positive ASPIRE PhasePhase 3 clinical trial will be sufficient to support regulatory submissions around the world." The full research reports on Amgen are available to download free of charge at:
...tolerated, including in quite elderly patients," Nowakowski explained during a presentation of the study results at the 2014 ASCO Annual Meeting. "The efficacy of this combination appears to be promising when compared to R-CHOP therapy. It appears that the addition of lenalidomide may ameliorate the negative effect of the non-GCB phenotype on outcomes."
...Marc Mansour, chief executive officer of Immunovaccine. "Importantly, this first association of DPX-Survivac with a clinical benefit has generated interest from key opinion leaders from around the world, who have expressed a desire to collaborate with Immunovaccine on future clinical trials."

More Content

All (141) | News (125) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Researchers from Medical University Describe Fi... [Published Street Sweeper - 2 hours ago]
CLL's 'Very Unusual Year' [Published General Medicine eJournal - 2 hours ago]
Drug Approvals, Clinical Trial Result, and Phil... [Published TickerTech.com - 11 hours ago]
Clinigen Group Further Strengthens Oncology Sup... [Published Fat Pitch Financials - 18 hours ago]
Lenalidomide Plus R-CHOP Effective in Aggressiv... [Published OncLive - Aug 20 2014]
Carilzomib Alone Not Effective for Refractory M... [Published Chemotherapy Advisor - Aug 19 2014]
New R-CHOP Regimen Promising in DLBCL Subtype [Published Cancernetwork.com - Aug 18 2014]
Amgen Reports Results from Kyprolis Trial [Published Individual.com - Aug 18 2014]
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Amgen's phase 3 FOCUS trial of Kyprolis in pati... [Published PharmaBiz - Aug 16 2014]
Activated microglia contribute to neuronal apop... [Published 7thSpace - Aug 15 2014]
Kyprolis fails to meet primary endpoint in mult... [Published Orthopedics Today - Aug 15 2014]
The Zacks Analyst Blog Highlights: Amgen, ANN, ... [Published Industrial Info Financials - Aug 15 2014]
Immunovaccine Announces Financial Results for Q... [Published BusinessWeek - Aug 15 2014]
Kyprolis fails to wow in survival trial [Published Medical Marketing And Media - Aug 15 2014]
Amgen hit as Kyprolis fails myeloma study [Published PMLive - Aug 15 2014]
New Research Presented in Wilms Tumor, Pediatri... [Published The ASCO Post - Aug 15 2014]
Amgen's FOCUS Study on Multiple Myeloma Drug Ky... [Published Zacks.com - Aug 14 2014]
Amgen Multiple Myeloma Drug Misses Phase 3 Endp... [Published Drug Discovery and Development - Aug 14 2014]
Healthcare Review: NewLink Genetics, Cellular B... [Published BioMedReports - Aug 14 2014]
Kyprolis trial misses endpoint in myeloma [Published MedNous - Aug 14 2014]
Amgen’s Kyprolis failed to meet primary endpoin... [Published Pharma Letter - Aug 14 2014]
Amgen cancer drug fails key test [Published Pharmafocus - Aug 14 2014]
HSV-Related Oral Mucositis in Patients With Lym... [Published General Medicine eJournal - Aug 14 2014]
"Precursors to Echogenic Polymer Microcapsules ... [Published HispanicBusiness.com - Aug 14 2014]
Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a B... [Published Motley Fool - Aug 14 2014]
Genmab's (GNMSF) CEO Jan Winkel on Q2 2014 Resu... [Published Seeking Alpha - Aug 14 2014]
Amgen Blood Cancer Drug Fails Primary Endpoint ... [Published RTTNews.com - Aug 13 2014]
Amgen cancer drug fails Phase 3 trial [Published Seeking Alpha - Aug 13 2014]
Amgen Says Phase 3 Focus Trial Fails To Meet Pr... [Published RTTNews.com - Aug 13 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ...
Research and Markets: Cyclophosphamide (CAS 605... [Published Business Wire Manufacturing News - Aug 07 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/63jzc7/cyclophosphamide) has announced the addition of the "Cyclophosphamide (CAS 6055-19-2, 50-18-0) Market Research Report 2014" report to their offering. Cyclophosphamide ...
Autologous hematopoietic stem cell transplantat... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Jul 30 2014]
Background: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. Objective: The European Group for ...
Rebound post-natallizumab: it is not as bad as ... [Published Multiple Sclerosis Research - Jul 20 2014]
Rebound post-natalizumab: is it such a problem? #MSBlog #MSResearch "The study below reports MS rebound post-natalizumab. They make a general statement that 'no treatment is unable to abolish disease activity reactivation after natalizumab discontinuation' ...
Fatherhood and MS medications [Published MSology - Jul 10 2014]
A great deal has been written about MS and pregnancy. The general rule of thumb is that women who plan to become pregnant should interrupt their MS medication, then resume treatment once the baby is born. (For more on this topic, see Is it Safe to ...
1 2 3

Press Releases

sort by: Date | Relevance
Nuvilex and Austrianova Announce Results of Cli... [Published GlobeNewswire: Acquisitions News - Jul 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.